Life Science Insights 360 Podcasts

We are honored to welcome Dr. Ron Cohen, CEO of Oryon Cell Therapies and a distinguished leader in the biotechnology industry.With more than three decades of experience building innovative biotech companies, raising significant capital, and advancing therapies for patients, Dr. Cohen has made a lasting impact on the life sciences community.At Oryon Cell Therapies, he is leading the development of next-generation cell therapies with a focus on neurodegenerative diseases and the potential of regenerative medicine to address some of the most challenging conditions in healthcare.In this conversation, we explore his entrepreneurial journey, leadership lessons, biotech financing, the rapidly evolving field of cell therapy, and his vision for the future of regenerative medicine.Key Topics Discussed#Dr. Ron Cohen’s three-decade journey in biotechnology and entrepreneurship#What inspired him to pursue biotech rather than a traditional medical career#Lessons learned from setbacks and challenges throughout his entrepreneurial journey#His leadership philosophy and how it has evolved over the past 30 years#Why he joined Oryon Cell Therapies and his vision for its next chapter#The evolution of cell therapy and regenerative medicine#Scientific opportunities that were not possible just five years ago#What differentiates Oryon Cell Therapies in the regenerative medicine landscape#The potential of cell therapy in treating neurodegenerative diseases#Therapeutic areas where cell therapy could deliver major breakthroughs#Raising more than $1.1 billion in capital throughout his career#Advice for first-time biotech founders seeking investment#What investors look for in successful biotech CEOs beyond great science#Building resilient organizations and high-performance biotech teams#Creating a culture that thrives through both successes and setbacksEpisode Highlights#The Future of Cell Therapy — Exploring how advances in cell biology and regenerative medicine are opening new possibilities for treating complex diseases.#Neurodegenerative Diseases — Understanding the potential of next-generation cell therapies to address some of the most challenging neurological conditions.#Biotech Entrepreneurship — Dr. Cohen shares lessons from more than 30 years of building companies and advancing innovative therapies.#Raising Capital — Insights into biotech fundraising, investor expectations, and what founders need to demonstrate beyond compelling science.#Leadership & Culture — Practical lessons on building teams, navigating setbacks, and creating organizations capable of sustained innovation.#The Future of Biotechnology — Dr. Cohen shares his perspective on where cell therapy and regenerative medicine are heading and the opportunities that lie ahead.Whether you’re a biotech entrepreneur, scientist, physician, investor, pharmaceutical executive, cell therapy researcher, or healthcare innovator, this episode provides valuable perspectives on the science, business, and leadership shaping the next generation of biotechnology.Subscribe for conversations with leaders across biotechnology, pharmaceuticals, healthcare, clinical research, AI, cell therapy, and life sciences.#LifeScienceInsights360 #RonCohen #OryonCellTherapies #CellTherapy #Biotechnology #RegenerativeMedicine #NeurodegenerativeDiseases #Biotech #DrugDevelopment #LifeSciences #HealthcareInnovation #BiotechEntrepreneur #BiotechLeadership #VentureCapital #ClinicalResearch

Dr. Shneider is pioneering innovative approaches to cancer treatment through Elenagen, a novel biological therapeutic being investigated for difficult-to-treat cancers. His unique approach connects human and veterinary oncology, advancing the One Health vision while challenging conventional approaches to biotechnology development.In this conversation, we explore Dr. Shneider’s journey in biotechnology and oncology, the science behind Elenagen, clinical development, cancer immunology, and the potential of combining human and veterinary research to accelerate therapeutic innovation.Key Topics Discussed#Dr. Alexander Shneider’s journey into biotechnology and oncology#The mission and vision behind CureLab Oncology#Understanding Elenagen and its novel approach to cancer treatment#How Elenagen interacts with the immune system#The role of chronic inflammation in cancer#Clinical development and research in difficult-to-treat cancers#Insights into platinum-resistant ovarian cancer#Combining innovative therapies with chemotherapy and immunotherapy#The philosophy of going “from the drug to the mechanism”#Challenging traditional biotechnology development models#The One Health connection between human and veterinary oncology#Cancer research in dogs and its potential relevance to human medicine#How veterinary medicine can contribute to human drug development#Capital-efficient biotech development and innovation#Leadership lessons from building CureLab#The future of cancer treatment, biotechnology, and precision medicineEpisode Highlights#A deep dive into the science and potential of Elenagen#Dr. Shneider’s perspective on the relationship between cancer, inflammation, and immunity#How human and veterinary oncology can work together under the One Health approach#Insights into innovative and capital-efficient biotech development#Perspectives on the future of cancer therapeutics and biotechnology innovation#Leadership and entrepreneurship lessons from a scientist building companies around novel cancer therapiesWhether you're a biotechnology professional, oncologist, researcher, physician, investor, entrepreneur, or healthcare innovator, this episode offers valuable insights into the science, strategy, and innovation shaping the future of cancer treatment.#LifeScienceInsights360 #AlexanderShneider #CureLabOncology #Elenagen #Oncology #CancerResearch #CancerTreatment #Biotechnology #PrecisionMedicine #OneHealth #VeterinaryOncology #DrugDevelopment #Pharma #LifeSciences #HealthcareInnovation

With more than two decades of experience across organizations including West Pharmaceutical Services and Catalent, Elizabeth brings deep expertise in transforming scientific innovation into scalable solutions that help biopharma companies accelerate drug development and bring innovative therapies to patients.Our conversation explores the evolution of the CDMO industry, AustinPx’s innovative KinetiSol® technology, formulation and bioavailability challenges, and the future of pharmaceutical manufacturing and drug delivery.Elizabeth also shares her perspective on how AI, data-driven decision-making, predictive analytics, machine learning, and digital technologies are transforming drug development and manufacturing. We discuss personalized medicine, emerging drug delivery technologies, building high-performing teams, and the leadership principles required to successfully scale a science-driven organization.Drawing from her extensive industry experience, Elizabeth offers valuable insights into how pharmaceutical companies and their development partners can accelerate innovation, overcome complex formulation challenges, and prepare for the future of medicine.Key Topics Discussed#Elizabeth Hickman’s career journey from West Pharmaceutical Services and Catalent to AustinPx#Leadership lessons from more than 20 years in the CDMO industryAustinPx’s innovative approach to pharmaceutical development#What differentiates AustinPx from traditional CDMOsKinetiSol® technology and how it is transforming pharmaceutical formulation#How KinetiSol can help improve bioavailability and address challenging drug candidates#Reducing drug development timelines and manufacturing complexity#Drug formulation challenges facing pharmaceutical and biotech companies#How CDMOs are evolving into strategic innovation partners#Differences between the needs of emerging biotech companies and large pharmaceutical organizations#The growing role of AI, machine learning, predictive analytics, and data-driven decision-making#The potential of digital twins in pharmaceutical manufacturing#Balancing scientific innovation with business growth#Building high-performing, client-focused teams#The impact of personalized medicine on pharmaceutical manufacturing#Emerging drug delivery technologies that could shape the next decade#The future of the global CDMO industryEpisode Highlights#Pharmaceutical Innovation — Elizabeth shares her perspective on turning scientific breakthroughs into scalable pharmaceutical solutions.#KinetiSol® Technology — A closer look at AustinPx’s innovative technology platform and its potential to overcome challenging formulation and bioavailability issues.#The Evolution of CDMOs — How CDMOs are moving beyond traditional manufacturing services to become strategic partners throughout the drug development journey.#AI & Digital Transformation — Exploring how artificial intelligence, predictive analytics, machine learning, and data are changing formulation development and manufacturing.#Future of Drug Delivery — Insights into personalized medicine, emerging delivery technologies, and the changing needs of next-generation therapies.#Leadership & Growth — Elizabeth shares lessons on building strong teams, creating a client-centric culture, and leading through a rapidly changing pharmaceutical landscape.#Industry Outlook — Where Elizabeth sees pharmaceutical manufacturing and the CDMO industry heading over the next five to ten years.#LifeScienceInsights360 #ElizabethHickman #AustinPx #PharmaceuticalDevelopment #DrugDevelopment #DrugDelivery #CDMO #PharmaInnovation #KinetiSol #PharmaceuticalManufacturing #Biotechnology #AIinPharma #DigitalTransformation #PersonalizedMedicine #LifeSciences #HealthcareInnovation #Pharma #Biotech

In this episode of Life Science Insights 360, I'm delighted to welcome Ivanna Rosendal, Vice President of Business Digitalization, a global leader driving digital transformation across clinical development, pharmacovigilance, commercial, and medical organizations.Beyond her executive leadership role, Ivanna is also an author, podcast host, and stand-up comedian, bringing a unique perspective on innovation, leadership, organizational change, and the human side of digital transformation. Drawing from her extensive experience, she shares how life sciences organizations can successfully navigate technological disruption while keeping people, patients, and purpose at the center of innovation.Our conversation explores the future of AI-powered drug development, digital transformation, decentralized clinical trials, leadership in highly regulated industries, and how emerging technologies are reshaping the future of healthcare.## Key Topics Discussed- Ivanna Rosendal's career journey and leadership in business digitalization.- Driving enterprise-wide digital transformation across clinical development, pharmacovigilance, commercial, and medical organizations.- The biggest leadership challenges in implementing digital transformation within highly regulated life sciences companies.- How artificial intelligence is transforming clinical development and accelerating innovation.- The importance of data quality, interoperability, and connected digital ecosystems.- Why digital transformation initiatives succeed—or fail—and lessons for organizational change.- The future of decentralized and hybrid clinical trials.- Leveraging real-world data and real-world evidence to improve clinical decision-making.- Emerging technologies including AI agents, predictive analytics, digital twins, and intelligent automation.- Building cultures that embrace innovation, continuous learning, and change.- Leadership lessons for developing the next generation of life sciences professionals.- Balancing executive leadership with writing, podcasting, and stand-up comedy, and how storytelling and humor strengthen communication and leadership.## Episode Highlights- Expert insights into digital transformation across the life sciences industry.- A forward-looking discussion on AI, data strategy, and the future of clinical development.- Practical leadership advice for driving organizational change and innovation.- Perspectives on emerging technologies that are reshaping drug development and healthcare.- An inspiring conversation about leadership, creativity, communication, and the value of bringing authenticity and humor into the workplace.Whether you're a life sciences executive, digital transformation leader, clinical research professional, healthcare innovator, technology enthusiast, or aspiring leader, this episode offers valuable insights into the strategies, technologies, and leadership principles shaping the future of life sciences.

In this episode of the Life Science Insights Podcast , I'm delighted to welcome Dr. Faisal Mehmud, Chief Medical Officer of Medicus Pharma , a clinical-stage biotechnology company focused on developing innovative therapies for oncology and other high unmet medical needs.With an exceptional career spanning global pharmaceutical leaders including Sanofi, Novartis, Bristol Myers Squibb, Pfizer, and GSK , Dr. Mehmud shares his journey through clinical development, medical leadership, and drug innovation. We explore how Medicus Pharma is advancing novel therapeutic approaches for skin cancer and prostate cancer, and discuss the future of precision oncology, artificial intelligence, and patient-centered drug development.Our conversation highlights the company's lead programs, SkinJect and Teverelix , along with broader industry trends that are transforming clinical research, oncology, and the development of next-generation therapies.## Key Topics Discussed- Dr. Faisal Mehmud's career journey and leadership across global pharmaceutical companies.- Medicus Pharma's mission and its approach to developing innovative oncology therapies.- The science behind SkinJect , a dissolvable microneedle patch designed for localized treatment of skin cancer.- The advantages of localized drug delivery compared with traditional systemic chemotherapy.- Key insights from the Phase 2 clinical study of SkinJect.- An overview of Teverelix and its potential role in treating prostate cancer.- The importance of cardiovascular safety in oncology drug development.- Emerging trends improving the efficiency of clinical trials.- How artificial intelligence and digital technologies are transforming clinical development.- Medicus Pharma's partnership strategy and the value of advancing programs through Phase 2 before strategic collaborations.- The evolution of precision oncology and innovation across the pharmaceutical industry.- Leadership insights, career advice for the next generation of physicians and scientists, and the future outlook for biotechnology innovation.## Episode Highlights- Expert insights into the future of precision oncology and innovative cancer therapeutics.- A deep dive into SkinJect and Teverelix, two promising programs addressing significant unmet medical needs.- Perspectives on AI, digital transformation, and the future of clinical development.- Leadership lessons from decades of experience across some of the world's leading pharmaceutical companies.- A forward-looking discussion on biotechnology innovation, strategic partnerships, and improving outcomes for cancer patients.Whether you're a biotechnology professional, oncologist, clinical researcher, life sciences executive, investor, or healthcare innovator, this episode offers valuable insights into the technologies, strategies, and scientific advances shaping the future of cancer care and precision medicine.

In this episode of the Life Science Insights Podcast, I'm delighted to welcome Dr. John Craighead, CEO of Syntax Bio, a synthetic biology company advancing the next generation of programmable stem cell therapies.With more than 20 years of leadership experience across biotechnology, corporate strategy, and life sciences, Dr. Craighead has held executive leadership roles at organizations including GRAIL, Sanofi, Atara Biotherapeutics, HALO Precision Diagnostics, and now Syntax Bio. He shares his journey from cell biology research to leading innovative biotechnology companies and discusses how scientific innovation, strategic partnerships, and advanced manufacturing are shaping the future of regenerative medicine.Our conversation explores Syntax Bio's mission to engineer programmable stem cell therapies, the challenges of scaling cell-based therapeutics, and the role of synthetic biology, computational biology, and artificial intelligence in accelerating the next generation of precision medicine. We also discuss the company's strategic collaboration with Applied StemCell, biotechnology funding, and the future of programmable cell engineering.## Key Topics Discussed* Dr. John Craighead's career journey from cell biology research to biotechnology leadership.* Leadership lessons from GRAIL, Sanofi, Atara Biotherapeutics, and Syntax Bio.* Syntax Bio's mission to develop programmable stem cell therapies.* The scientific and manufacturing challenges of stem-cell-based therapeutics.* Improving the speed, consistency, and scalability of therapeutic cell manufacturing.* The strategic collaboration between Syntax Bio and Applied StemCell and its impact on innovation.* The growing role of synthetic biology in advancing regenerative medicine.* How computational biology and artificial intelligence are accelerating therapeutic discovery and development.* Balancing personalized therapies with scalable manufacturing.* Building high-performing biotechnology organizations and leading multidisciplinary teams.* The importance of strategic partnerships and investment in advancing biotechnology innovation.* Trends shaping the future of synthetic biology, regenerative medicine, and programmable cell therapies.## Episode Highlights* Insights into the future of programmable stem cell therapies and regenerative medicine.* Expert perspectives on synthetic biology and next-generation therapeutic innovation.* A discussion on manufacturing challenges and scaling advanced cell therapies.* How AI, computational biology, and automation are transforming biotechnology research and development.* Leadership lessons on innovation, strategy, fundraising, and building world-class biotechnology companies.* A forward-looking conversation on the future of precision medicine and engineered cell therapies.Whether you're a biotechnology professional, life sciences executive, researcher, investor, entrepreneur, or student, this episode offers valuable insights into one of the fastest-evolving areas of modern medicine and the technologies that are redefining the future of healthcare.

In this episode of the Life Science Insights Podcast, we sit down with Jimmy Bechtel, Chief Strategy & Site Solutions Officer (CSSO) at the Society for Clinical Research Sites (SCRS), to explore the evolving landscape of clinical research and the critical role research sites play in advancing innovation, improving patient outcomes, and driving more efficient clinical trials.Jimmy shares his perspective on the challenges facing research sites today, the growing importance of site sustainability, and how technology, AI, and stronger collaboration between sponsors, CROs, and research sites are shaping the future of clinical research. We also discuss how patient-centric approaches, operational excellence, and digital transformation are redefining the clinical trial ecosystem.Key Topics DiscussedJimmy Bechtel's professional journey into clinical research and site managementThe meaning of site success in today's clinical trial environmentMajor operational challenges facing clinical research sitesThe growing importance of long-term site sustainabilityStrengthening collaboration between research sites, sponsors, and CROsLeveraging technology to improve site efficiency and reduce administrative burdenThe evolution of decentralized and hybrid clinical trialsStrategies for improving patient engagement and retentionAddressing workforce shortages in clinical researchThe impact of AI and automation on site operationsImproving interoperability and workflow integrationAdvancing diversity, accessibility, and inclusion in clinical trialsBuilding resilient and sustainable research programsEmerging trends shaping the next generation of clinical research sitesEpisode Highlights✔ Expert insights into the challenges and opportunities facing modern clinical research sites✔ Perspectives on AI, digital transformation, and technology-enabled clinical trials✔ Practical strategies for improving site sustainability and operational efficiency✔ A discussion on patient-centric trial design, accessibility, and engagement✔ A forward-looking vision for the future of clinical research and patient careSubscribe to the Life Science Insights Podcast for more conversations with industry leaders, innovators, and experts shaping the future of clinical research, biotechnology, and healthcare.#LifeScienceInsights #ClinicalResearch #ClinicalTrials #SCRS #JimmyBechtel #ResearchSites #SiteManagement #PatientCentricity #DecentralizedTrials #AIInHealthcare #DigitalHealth #Biotechnology #HealthcareInnovation #ClinicalOperations #FutureOfClinicalResearch

In this episode of the Life Science Insights Podcast, we sit down with Mark Van Zee, Founder and CEO of Saku Biosciences, to explore the future of scalable biology and how innovations in cell line development are transforming modern biomanufacturing. Mark shares his journey from bioengineering research to entrepreneurship and explains why the greatest challenge facing biotechnology today is not scientific discovery—but scaling innovation to deliver real-world impact.From breakthrough PicoShell® technology to the future of automation, sustainable biomanufacturing, and next-generation cell engineering, this conversation examines how advanced technology platforms are accelerating drug development, improving manufacturing efficiency, reducing costs, and expanding global access to innovative therapies.Key Topics DiscussedMark Van Zee's journey from bioengineering research to founding Saku BiosciencesWhy biotechnology faces a scalability challenge rather than an R&D challengeUnderstanding PicoShell® technology and its applicationsAccelerating cell line development through advanced screening technologiesThe impact of high-performing producer cells on biomanufacturing efficiencyKey factors biopharma companies consider when evaluating new technology platformsThe role of automation and advanced screening in eliminating development bottlenecksStrengthening biomanufacturing supply chains through modern technologiesSustainable biotechnology and the importance of alternative feedstocksReducing downstream processing costs through improved cell engineeringChallenges and opportunities in scaling biotechnology innovationsBalancing scientific innovation with fundraising and commercializationLessons learned while building Saku BiosciencesThe future of scalable biology across healthcare, food, and industrial biotechnologyEpisode Highlights✔ Why scaling remains one of biotechnology's greatest challenges✔ How PicoShell® technology is transforming cell line development✔ The growing role of automation in modern biomanufacturing✔ Strategies for building more resilient and sustainable biotech supply chains✔ Insights into commercializing breakthrough biotechnology platforms✔ A forward-looking vision for scalable biology and its impact across healthcare and industrySubscribe to the Life Science Insights Podcast for more conversations with innovators, entrepreneurs, and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SakuBiosciences #Biotechnology #Biomanufacturing #CellLineDevelopment #Bioprocessing #Biopharma #SyntheticBiology #LifeSciences #HealthcareInnovation #Bioengineering #Automation #ScalableBiology #BiotechPodcast #DrugDevelopment

In this episode of the Life Science Insights Podcast, we sit down with Dr. Raviv Pryluk, CEO and Co-Founder of PhaseV, to explore how artificial intelligence and causal machine learning are transforming clinical development. Dr. Pryluk explains how AI-driven trial optimization is making clinical trials faster, smarter, and more efficient—while reducing costs, minimizing risk, and improving the probability of success.We discuss PhaseV's innovative approach to adaptive, causal, and data-driven clinical development, the growing role of AI in clinical decision-making, and how next-generation technologies are helping sponsors design more efficient, personalized, and successful clinical trials.Key Topics DiscussedUnderstanding adaptive, causal, and data-driven clinical developmentHow causal machine learning differs from traditional AI approachesDefining AI-driven clinical trial optimization in practical termsHow PhaseV's Trial Optimizer enhances trial efficiency while reducing costsBalancing statistical rigor with real-world clinical trial constraintsReal-world examples of AI-driven trial optimizationMajor inefficiencies in today's clinical trial ecosystemUsing AI and machine learning to de-risk drug developmentRegulatory perspectives on AI-enabled clinical trial designBuilding trust, transparency, and interpretability in AI-driven decision-makingAddressing data variability and bias across diverse patient populationsLeadership lessons from building and scaling an AI-driven healthcare companyBuilding multidisciplinary teams across AI, biology, and clinical researchThe future of clinical trials: smaller, faster, and more personalized studiesThe long-term impact of AI on the economics of drug developmentEpisode Highlights✔ A clear explanation of causal machine learning and why it matters✔ How AI is optimizing trial design, patient selection, and clinical outcomes✔ Strategies for reducing clinical trial costs, timelines, and development risk✔ The importance of explainable and trustworthy AI in clinical decision-making✔ Leadership insights from building and scaling an AI-first healthcare company✔ A forward-looking vision for the future of AI-powered clinical developmentSubscribe to the Life Science Insights Podcast for more conversations with innovators, researchers, and industry leaders advancing the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #PhaseV #ArtificialIntelligence #ClinicalTrials #DrugDevelopment #MachineLearning #CausalAI #ClinicalResearch #PrecisionMedicine #Biotechnology #HealthcareInnovation #DigitalHealth #LifeSciences #AIInHealthcare #BiotechPodcast

In this episode of the Life Science Insights Podcast, we sit down with Karsten Eastman, CEO and Co-founder of Sethera Therapeutics, to explore how innovative enzyme-based technologies are transforming drug discovery. Karsten shares the inspiration behind founding Sethera, the scientific challenges the company is addressing, and how its unique platform is enabling the discovery of next-generation peptide therapeutics for difficult-to-treat diseases.We discuss the power of enzymes in drug discovery, the promise of enzymatically constrained peptides, the role of AI and data in modern biotechnology, and the future of peptide-based medicines.Key Topics Discussed:The inspiration behind founding Sethera TherapeuticsThe unmet needs in drug discovery that Sethera aims to addressAn overview of Sethera's technology platform and missionWhat differentiates Sethera from other biotech companiesUnderstanding enzyme-enabled drug discovery in simple termsWhy enzymes are powerful tools for creating novel medicinesThe science and potential of enzymatically constrained peptidesAddressing hard-to-treat diseases and previously undruggable targetsDiscovering therapies for previously inaccessible biological targetsHow Sethera identifies, screens, and optimizes new moleculesThe role of data, AI, and machine learning in drug discoveryChallenges and lessons learned while building a biotechnology companyBalancing scientific innovation with business growth and executionBuilding high-performing, multidisciplinary biotech teamsEmerging trends shaping the future of biotechnology and drug discoveryThe future impact of peptide-based therapeutics on healthcareEpisode Highlights✔ The founding story behind Sethera Therapeutics✔ A simple explanation of enzyme-enabled drug discovery✔ Why constrained peptides represent an exciting new therapeutic class✔ How biotechnology is expanding the range of druggable targets✔ The growing role of AI, data, and advanced platforms in drug discovery✔ A vision for the future of precision medicine and patient careSubscribe to the Life Science Insights Podcast for more conversations with innovators and industry leaders shaping the future of biotechnology, life sciences, and healthcare.#LifeScienceInsights #SetheraTherapeutics #DrugDiscovery #Biotechnology #PeptideTherapeutics #Biotech #LifeSciences #PrecisionMedicine #DrugDevelopment #Enzymes #AIinBiotech #HealthcareInnovation #Biopharma #LifeSciencePodcast #futureofmedicine